Pancreatic cancer and its metastases might have their days numbered, according to a study published in The Journal of Experimental Medicine.
Despite substantial progress in treating pancreatic cancer, this disease is still considered largely incurable. The poor prognosis is mostly due to metastases to other vital organs, a process driven by soluble factors present in the tumor environment.
A secreted immune protein called interleukin(IL)-17 has been associated with cancer progression, and receptors for IL-17 are expressed in the pancreas. Wen-Hwa Lee and colleagues from the Academia Sinica in Taiwan now show that one type of IL-17 (IL-17B) and its receptor are highly expressed in pancreatic cancer, and their levels correlate with poor patient survival. In mice, secretion of IL-17B promoted the growth and metastasis of pancreatic cancer cells and enhanced the recruitment of inflammatory cells to the tumor site. Treating tumor-bearing mice with a drug that prevented IL-17B from binding to its receptor halted tumor growth and spread, resulting in increased survival.
Since metastases are the leading cause of death in pancreatic cancer patients, this drug might represent a novel therapeutic approach to defeat pancreatic cancer and prolong patient survival.
Wu, H.-H., et al. 2015. J. Exp. Med. doi:10.1084/jem.20141702
About The Journal of Experimental Medicine
The Journal of Experimental Medicine (JEM) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by active scientists in conjunction with our in-house scientific editors. JEM content is posted to PubMed Central, where it is available to the public for free six months after publication. Authors retain copyright of their published works and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit http://www.jem.org .